Welcome to the world of Micreos...

Bacteria are all around us. Most of them are good and protect us, but some can cause irritation or infection. Antibiotics do not distinguish between bad and good bacteria and their use can lead to side effects and resistance. This renders them unsuitable for long-term use. As they have been broadly used - often inappropriately - the emergence of antibiotic-resistant 'superbugs' is now a global concern. On the other hand it has become evident that our microbiome, comprising billions of beneficial bacteria, is necessary for our health and should be left intact.

Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. The company is viewed as global leader spearheading this exciting new field. With Micreos endolysin technology, for the first time we can kill only the unwanted bacteria - including antibiotic resistant strains - while preserving the beneficial bacteria, essential for our health. In addition, scientists do not expect emergence of resistance against endolysins, based on their working mechanism. This unlocks a completely new approach in dealing with the bacteria around us - also enabling preventive daily therapy against only unwanted bacteria for as long as needed.

Micreos' Staphefekt SA.100 is an enzyme (endolysin), which kills only Staphylococcus aureus, including the resistant MRSA. Marketed under the Gladskin brand, it is suitable for daily maintenance therapy, for inflammatory skin conditions such as eczema and inflammatory acne and rosacea, and has already had a life changing impact for thousands of people. For further background information on SA.100 Fact sheets are available. Micreos's first pharmaceutical endolysin, XZ.700, is currently in a Phase I/IIA clinical trial for global registration for atopic dermatitis. Next targeted pharmaceutical indications include Diabetic Foot Ulcers, Cutaneous T-cell Lymphoma - based on excessive skin colonization by S. aureus - and Bloodstream Infections. 

Under the Phageguard brand Micreos has also developed FDA-approved food safety products against Salmonella and Listeria monocytogenes. More information is available at the Phageguard website.

The company is committed to helping mankind with products that are effective, sustainable and affordable. The company's products:

-  work fast

-  are easy to apply

-  have no known adverse effects

Micreos Technology Cenbtre Zurich is based in Wädenswil, close to Zurich. Micreos Pharmaceutical Development Team and manufacturing plant are based in Bilthoven at the RIVM premises (Dutch NIH). Micreos Food Safety is based in Wageningen 'Food Valley'. Micreos headquarters are located in The Hague, world capital of Peace and Justice. 

We work according to the highest ethical and professional standards, as witnessed by numerous awards and grants received over the past years, and publications in scientific journals and regular press. Micreos collaborates with top institutes and companies around the world and its advisors and partners have broad expertise in the fields in which we operate. Our long-term research partners include ETH Zurich, Switzerland, (Prof. Loessner) and Erasmus Medical Center Rotterdam (Prof. Pasmans, pediatric dermatology).